117 related articles for article (PubMed ID: 20670596)
21. Pharmacotherapy of neuroblastoma.
George RE; Diller L; Bernstein ML
Expert Opin Pharmacother; 2010 Jun; 11(9):1467-78. PubMed ID: 20408767
[TBL] [Abstract][Full Text] [Related]
22. Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Clin Cancer Res; 2003 Oct; 9(13):4835-40. PubMed ID: 14581355
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of DNA di-tetraploidy in neuroblastoma.
Ladenstein R; Ambros IM; Pötschger U; Amann G; Urban C; Fink FM; Schmitt K; Jones R; Slociak M; Schilling F; Ritter J; Berthold F; Gadner H; Ambros PF
Med Pediatr Oncol; 2001 Jan; 36(1):83-92. PubMed ID: 11464912
[TBL] [Abstract][Full Text] [Related]
24. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma.
Vandesompele J; Baudis M; De Preter K; Van Roy N; Ambros P; Bown N; Brinkschmidt C; Christiansen H; Combaret V; Lastowska M; Nicholson J; O'Meara A; Plantaz D; Stallings R; Brichard B; Van den Broecke C; De Bie S; De Paepe A; Laureys G; Speleman F
J Clin Oncol; 2005 Apr; 23(10):2280-99. PubMed ID: 15800319
[TBL] [Abstract][Full Text] [Related]
25. Reanalysis of neuroblastoma expression profiling data using improved methodology and extended follow-up increases validity of outcome prediction.
Schramm A; Mierswa I; Kaderali L; Morik K; Eggert A; Schulte JH
Cancer Lett; 2009 Sep; 282(1):55-62. PubMed ID: 19349112
[TBL] [Abstract][Full Text] [Related]
26. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group.
London WB; Castleberry RP; Matthay KK; Look AT; Seeger RC; Shimada H; Thorner P; Brodeur G; Maris JM; Reynolds CP; Cohn SL
J Clin Oncol; 2005 Sep; 23(27):6459-65. PubMed ID: 16116153
[TBL] [Abstract][Full Text] [Related]
27. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification.
Oberthuer A; Berthold F; Warnat P; Hero B; Kahlert Y; Spitz R; Ernestus K; König R; Haas S; Eils R; Schwab M; Brors B; Westermann F; Fischer M
J Clin Oncol; 2006 Nov; 24(31):5070-8. PubMed ID: 17075126
[TBL] [Abstract][Full Text] [Related]
28. [Genetic alterations in neuroblastoma and their usefulness for clinical management].
Normand C; Michon J; Janoueix-Lerosey I; Delattre O; Schleiermacher G
Bull Cancer; 2011 May; 98(5):477-88. PubMed ID: 21609891
[TBL] [Abstract][Full Text] [Related]
29. At the frontier of progress for paediatric oncology: the neuroblastoma paradigm.
Moreno L; Marshall LV; Pearson AD
Br Med Bull; 2013; 108():173-88. PubMed ID: 24211816
[TBL] [Abstract][Full Text] [Related]
30. Neuroblastoma genetics and phenotype: a tale of heterogeneity.
Speleman F; De Preter K; Vandesompele J
Semin Cancer Biol; 2011 Oct; 21(4):238-44. PubMed ID: 21839839
[TBL] [Abstract][Full Text] [Related]
31. Progress towards personalized therapeutics: biologic- and risk-directed therapy for neuroblastoma.
Gustafson WC; Matthay KK
Expert Rev Neurother; 2011 Oct; 11(10):1411-23. PubMed ID: 21955198
[TBL] [Abstract][Full Text] [Related]
32. Quantitative modeling of clinical, cellular, and extracellular matrix variables suggest prognostic indicators in cancer: a model in neuroblastoma.
Tadeo I; Piqueras M; Montaner D; Villamón E; Berbegall AP; Cañete A; Navarro S; Noguera R
Pediatr Res; 2014 Feb; 75(2):302-14. PubMed ID: 24216542
[TBL] [Abstract][Full Text] [Related]
33. Genetic discoveries and treatment advances in neuroblastoma.
Bagatell R; Cohn SL
Curr Opin Pediatr; 2016 Feb; 28(1):19-25. PubMed ID: 26576010
[TBL] [Abstract][Full Text] [Related]
34. Research progress of neuroblastoma related gene variations.
Cao Y; Jin Y; Yu J; Wang J; Yan J; Zhao Q
Oncotarget; 2017 Mar; 8(11):18444-18455. PubMed ID: 28055978
[TBL] [Abstract][Full Text] [Related]
35. Overview and recent advances in the treatment of neuroblastoma.
Whittle SB; Smith V; Doherty E; Zhao S; McCarty S; Zage PE
Expert Rev Anticancer Ther; 2017 Apr; 17(4):369-386. PubMed ID: 28142287
[TBL] [Abstract][Full Text] [Related]
36. Neuroblastoma: a review of management and outcome.
Bhatnagar SN; Sarin YK
Indian J Pediatr; 2012 Jun; 79(6):787-92. PubMed ID: 22528697
[TBL] [Abstract][Full Text] [Related]
37. Meeting report--3rd Neuroblastoma Research Symposium, Liverpool, 6-7th November, 2013.
Bell E; Chen L; Viprey VF; Blanchard GB
Pediatr Blood Cancer; 2014 Sep; 61(9):1711-3. PubMed ID: 24803179
[TBL] [Abstract][Full Text] [Related]
38. Advances in neuroblastoma therapy.
MacFarland S; Bagatell R
Curr Opin Pediatr; 2019 Feb; 31(1):14-20. PubMed ID: 30480556
[TBL] [Abstract][Full Text] [Related]
39. New prognostic markers in neuroblastoma.
Navarro S; Piqueras M; Villamón E; Yáñez Y; Balaguer J; Cañete A; Noguera R
Expert Opin Med Diagn; 2012 Nov; 6(6):555-67. PubMed ID: 23480837
[TBL] [Abstract][Full Text] [Related]
40. Neuroblastoma.
Maris JM; Hogarty MD; Bagatell R; Cohn SL
Lancet; 2007 Jun; 369(9579):2106-20. PubMed ID: 17586306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
